Thiopurine Methyltransferase Activity and Thiopurine Metabolites in Inflammatory Bowel Disease. [PDF]
Crohns Colitis 360, 2020 El-Matary W.
europepmc +4 more sources
Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia
Turkish Journal of Hematology, 2015 Serhan Küpeli
doaj +2 more sources
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. [PDF]
Br J Haematol, 2015 Lennard L +3 more
europepmc +3 more sources
Genetic polymorphism of thiopurine S-methyltransferase in Argentina [PDF]
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2003 Background: Thiopurine methyltransferase (TPMT) catalyses the S-methylation of 6-thiopurine drugs, which are commonly used in the treatment of autoimmune diseases, leukaemia and organ transplantation. TPMT activity is polymorphic as a result of gene mutations.
Laura E. Laróvere +3 more
openalex +3 more sources
Thiopurine methyltransferase in acute lymphoblastic leukemia [PDF]
Blood, 2006 We recently reported that specific genetic polymorphisms, particularly polymorphisms in thymidylate synthase (TYMS) and glutathione S -transferase M1 (GSTM1) predicted the risk of relapse among children with acute lymphoblastic leukemia (ALL).[1][1] An accompanying commentary noted surprise that ...
Mary V. Relling +3 more
openalex +3 more sources
Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]
, 2016 Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven +7 more
core +14 more sources
gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease [PDF]
Intestinal Research, 2020 Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia.
Katsuyoshi Matsuoka
doaj +1 more source
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review [PDF]
Precision and Future Medicine, 2021 The development of treatment options has revolutionized the prognosis of inflammatory bowel disease (IBD). However, a particular group of patients still experience therapeutic failure or drug side effects.
Ji Young Chang, Jae Hee Cheon
doaj +1 more source
The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis. [PDF]
Br J Clin PharmacolAims Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6‐MMPR production and (sub)therapeutic 6‐TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD). This study evaluates the metabolic outcomes of switching to low‐dose thiopurine with allopurinol (LDTA) or thioguanine (TG) in IBD ...
Bayoumy AB +4 more
europepmc +2 more sources
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]
PLoS ONE, 2015 Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu +8 more
doaj +1 more source